Loading
BRCA Gene Mutations in Cancer / Breast Cancer Treatment Studies / Breast Lesions and Carcinomas · Journal article
Annals of Surgical Oncology · August 17, 2026
A consensus or society position rather than new primary data.
This is a multidisciplinary expert consensus statement on the management of invasive lobular carcinoma, synthesizing existing literature to provide clinical guidance distinct from ductal carcinoma management. The panel identifies key areas where ILC requires modified approaches: enhanced imaging for staging, careful attention to margin adequacy in lumpectomy, selective omission of axillary dissection in appropriate patients, neoadjuvant therapy selection by molecular rather than histologic subtype, and inclusion of CDH1 mutation analysis in genetic testing.
Expert consensus panel review. Expert panel addressing multidisciplinary management considerations for women with invasive lobular carcinoma. Las Vegas, Nevada, USA (panel meeting location).
Magnetic resonance imaging of the breast can improve accuracy of preoperative staging in ILC Surgeons should account for imaging limitations with respect to margin resection in lumpectomy for ILC Several trials with ILC subanalyses confirm safety of omission of axillary lymph node dissection in appropriately selected patients
Several trials with ILC subanalyses confirm safety of omission of axillary lymph node dissection in appropriately selected patients
Clinicians should recognize that ILC management differs meaningfully from ductal carcinoma and requires special consideration in imaging interpretation, surgical margins, axillary staging decisions, and genetic counselling. Treatment selection, particularly for neoadjuvant therapy, should prioritize molecular subtyping over histology alone.
Expert consensus panel review synthesizing literature on disease-specific management of invasive lobular carcinoma, providing multidisciplinary recommendations without presenting new primary data.
As stated by the source record.
Clinicians should recognize that ILC management differs meaningfully from ductal carcinoma and requires special consideration in imaging interpretation, surgical margins, axillary staging decisions, and genetic counselling. Treatment selection, particularly for neoadjuvant therapy, should prioritize molecular subtyping over histology alone.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Background Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer and presents histologically with a unique pattern of discohesive growth. An expert consensus panel was convened at the annual meeting of the American Society of Breast Surgeons to discuss disease specific management considerations and best practice when caring for women with ILC. Methods At the annual meeting of the American Society of Breast Surgeons held in Las Vegas, Nevada from April 30 to May 4, 2025, a panel convened to specifically address the intricacies of managing ILC. Panelists completed an independent literature review for each identified subtopic that was summarized and reviewed by panel moderators. Results The multidisciplinary management of ILC is nuanced and special considerations are essential to optimize treatment. Magnetic resonance imaging of the breast can improve the accuracy of preoperative staging. Surgeons should account for the limitations of imaging with respect to margin resection in lumpectomy. When considering the application of trials guiding omission of ALND in surgery for ILC, surgeons can rely on several studies that have included subanalyses of patients with ILC confirming safety in appropriately selected patients. Use of neoadjuvant therapy should be based on molecular subtype rather than tumor histology. Genetic testing for patients with ILC should include analysis of CDH1 mutations. Discussion Awareness and consideration of nuances around the management of ILC, including those discussed in the present study, can help clinicians provide optimal, evidenced based care to women presenting with ILC.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.